myotonia appears to turn up the damage happening in muscles
For generations, scientists have pursued the toxic RNA at the heart of myotonic dystrophy type 1 as the singular villain in a disease that slowly robs people of muscle, rhythm, and vitality. A team at the University of Rochester has now revealed that one of the disease's most familiar symptoms—muscle stiffness—is not merely a passenger but an active amplifier of the damage itself. Their findings, published in Nature Communications, suggest that the path toward healing may require addressing not only the genetic root but also the mechanism that turns up the volume on destruction.
- Myotonic dystrophy type 1 affects roughly one in five thousand people, progressively dismantling muscle function, heart rhythm, and quality of life with no cure in sight.
- A genetic mutation produces toxic RNA that disrupts thousands of genes—but researchers have long debated which downstream effects are truly driving the worst damage.
- University of Rochester scientists isolated muscle stiffness as an independent force of destruction, not just a symptom, by genetically correcting a single chloride channel defect in mouse models.
- When myotonia was corrected, mice showed greater muscle force, healthier tissue, and improved gene expression—even though the toxic RNA remained entirely intact in their cells.
- Existing stiffness-reducing drugs like mexiletine have largely been sidelined by side effects, but this research renews the case for developing safer versions as complements to RNA-targeted therapies.
- The field may be approaching a two-front strategy: silence the genetic root cause while simultaneously dampening the amplification loop that myotonia creates.
For nearly a century, researchers studying myotonic dystrophy type 1 have focused on a single genetic culprit—an abnormal DNA expansion that produces toxic RNA molecules, jamming the cellular machinery that reads thousands of genes correctly. The disease is relentless: progressive muscle weakness, wasting, heart rhythm problems, cataracts, and crushing fatigue. Scientists understood the toxic RNA as the root, but which of its many downstream effects drove the most damage remained unclear.
Now a team at the University of Rochester Medicine has reframed the question. Publishing in Nature Communications, they present evidence that muscle stiffness—myotonia—is not simply an uncomfortable side effect of DM1 but an active amplifier of the muscle damage itself. The disease begins when a mutated gene produces toxic RNA that traps proteins needed to process genetic instructions, cascading through the cell and disrupting hundreds of genes. Among the casualties is a chloride channel that helps muscles relax after contracting; when it fails, muscles become electrically overactive, producing the delayed relaxation known as myotonia.
To isolate myotonia's independent role, the researchers genetically corrected just the chloride channel defect in a DM1 mouse model—leaving the toxic RNA entirely intact. The results were far broader than expected. The mice not only lost their muscle stiffness but also generated greater muscle force, showed healthier tissue under the microscope, and experienced wide improvements in gene expression and RNA splicing. Myotonia, lead researcher John Lueck explains, functions like a 'volume knob' on the disease—turning it down improved muscle health even without touching the original mutation.
The implications reach into the clinic. RNA-targeted therapies in development have long used myotonia reduction as an early signal of success; this study suggests that reduction may itself be part of why muscle health improves. Drugs like mexiletine already exist to treat stiffness but have largely fallen out of use due to side effects. If safer formulations could be developed, they might serve as meaningful complements to advanced genetic therapies—or offer real benefit to patients who cannot yet access them. The finding points toward a two-front approach: address the genetic root while simultaneously silencing the amplification mechanism myotonia provides.
For nearly a century, scientists studying myotonic dystrophy type 1 have trained their attention on a single culprit: a genetic mutation that spawns toxic RNA molecules, which then jam up the cellular machinery responsible for reading thousands of genes correctly. The disease is relentless—progressive muscle weakness, wasting, the heart rhythm problems, the cataracts, the crushing daytime fatigue. Researchers understood that this toxic RNA was the root, but they remained uncertain which of its many downstream effects actually drove the most damage.
Now a team at the University of Rochester Medicine has reframed the question entirely. In a study published in Nature Communications, they present evidence that one of the disease's most visible symptoms—muscle stiffness, or myotonia—may be doing far more harm than anyone realized. It is not simply an uncomfortable side effect. It appears to be actively amplifying the muscle damage itself.
Myotonic dystrophy type 1 is the most common form of adult muscular dystrophy, an inherited disorder that strikes roughly one in five thousand people. The disease begins with an abnormal expansion of repeated DNA segments in the DMPK gene. Rather than producing a defective protein, this mutation creates a toxic RNA that traps the proteins needed to process genetic instructions correctly. The result cascades through the cell: hundreds to thousands of genes are improperly spliced, producing abnormal versions of proteins throughout the body. One particularly critical casualty is a chloride channel that helps muscles relax after they contract. When that channel is disrupted, muscles become electrically overactive, producing the delayed relaxation known as myotonia.
Most research has pursued a straightforward strategy: eliminate the toxic RNA itself. Several RNA-targeted therapies are now advancing toward clinical use. But John Lueck, an associate professor of pharmacology and physiology at the University of Rochester, and his colleagues asked a different question. Once myotonia develops, does it simply reflect the disease, or does it actively worsen the damage? Previous work from the same team had hinted at an answer. They found that when myotonia occurred alongside another splicing defect affecting calcium channels, muscle disease became dramatically worse in mice. Treating those mice with calcium channel-blocking drugs reversed many of the effects. That suggested muscle hyperexcitability might be directly contributing to degeneration.
To isolate myotonia's independent role, the researchers genetically corrected a single critical portion of the chloride channel gene in a mouse model of DM1. They expected to reduce muscle stiffness. What they found was far broader. The mice no longer developed muscle stiffness, but they also generated greater muscle force, showed healthier muscle tissue under the microscope, and experienced broad improvements in abnormal gene expression and RNA splicing. The toxic RNA remained present in the cells. But myotonia appeared to function as what Lueck describes as a "volume knob" on the disease—when they turned myotonia down, many aspects of muscle health improved, even though they had not corrected the original genetic mutation.
The implications are significant. Several experimental therapies in development are designed to eliminate the toxic RNA. Researchers have long used improvements in myotonia as an early sign that these therapies are working. The new study suggests that reducing myotonia may itself contribute substantially to improved muscle health. In other words, treating myotonia may do more than relieve stiffness; it may actually help slow or reduce the muscle damage caused by the disease.
Existing medications that reduce myotonia—drugs such as mexiletine and ranolazine—have largely fallen out of favor. Although they can improve muscle stiffness, side effects often limit their long-term use, and many people with DM1 never receive them. But if safer, better-tolerated versions could be developed, they could become an important complement to RNA-based therapies, or provide meaningful benefit for patients who lack access to those advanced treatments. The finding suggests that the path forward may not be either-or, but both: address the root genetic cause while simultaneously dampening the amplification mechanism that myotonia provides.
Notable Quotes
Myotonia isn't simply an uncomfortable symptom people experience. It appears to amplify the harmful effects of the disease in muscles.— John Lueck, associate professor of pharmacology and physiology at University of Rochester Medicine
The toxic RNA is still present. But myotonia appears to turn up the damage happening in muscles. When we turned myotonia down, many aspects of muscle health improved.— John Lueck
The Hearth Conversation Another angle on the story
So for decades, researchers have been chasing the toxic RNA. Why did it take this long to ask whether the stiffness itself was making things worse?
Because the stiffness looked like a symptom, not a driver. When you have a disease caused by a genetic mutation, you focus on the mutation. The stiffness was just one of many downstream effects. It took a specific experiment—removing myotonia while leaving the toxic RNA intact—to show that the stiffness was actively amplifying damage.
And when they removed the stiffness in the mice, what surprised them most?
That the improvement went far beyond just relaxation. The muscles generated more force. The tissue looked healthier under the microscope. Gene expression improved. It was as if they'd turned down the volume on the entire disease process, not just one symptom.
Does this mean the existing drugs for stiffness—mexiletine, ranolazine—should be brought back?
Not immediately. Those drugs have real side effects that limited their use. But the study suggests they deserve a second look, and that developing safer versions could be genuinely valuable. Right now, many patients with DM1 never get them.
What about the RNA therapies that are coming?
They're still crucial. But this research suggests they don't have to be the only approach. You could potentially use both—attack the root cause with RNA therapy while also dampening the amplification mechanism with better myotonia drugs. It's not either-or.
So the stiffness is like a volume knob?
Exactly. The toxic RNA is the underlying problem. But myotonia turns up the damage. When you turn myotonia down, the disease still exists, but it hurts less.